ArticleFrontiers in medicine2026
Case Report: Ischemic central retinal vein occlusion in a patient with relapsed mantle cell lymphoma as a manifestation of suspected cancer-associated hypercoagulability.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic central retinal vein occlusion (ischemic CRVO) is a severe, vision-threatening vascular event. While most cases stem from conventional cardiovascular or local anatomical etiologies, its presentation in association with relapsed mantle cell lymphoma (MCL) and suspected cancer-associated hypercoagulability is rare. This report highlights that retinal vascular occlusion in a patient with relapsed MCL represents a rare ocular manifestation of severe systemic prothrombotic activity. Case presentation: An 89-year-old male with established stage IV MCL (CD20+, cyclin D1+, SOX-11+, Ki-67∼10%), whose systemic relapse had been documented 6 months prior, developed sudden, painless vision loss in his right eye (best-corrected visual acuity, BCVA 0.01) while hospitalized for disease management. Multimodal ophthalmic examination and optical coherence tomography (OCT) supported the diagnosis of ischemic CRVO with prominent macular edema. Laboratory workup revealed marked coagulation abnormalities (D-dimer 4.34 mg/L FEU, Fibrinogen Equivalent Units; antithrombin activity 78%). Cranial MRI (magnetic resonance imaging) revealed multifocal chronic/non-acute ischemic cerebral changes and periventricular leukoaraiosis without acute diffusion restriction. Following a localized peribulbar injection of triamcinolone acetonide (20 mg), right eye BCVA improved to 0.1, with anatomical reduction of retinal edema. Prophylactic panretinal photocoagulation (PRP) was unfeasible due to posterior capsular opacification and severe systemic frailty. Four months later, the patient developed neovascular glaucoma requiring cyclocryotherapy for palliative pain management. Conclusions: In patients with active relapsed MCL, ischemic CRVO may occur as a focal manifestation of a generalized prothrombotic state. When severe retinal vascular occlusion presents in patients with advanced hematological malignancies, systemic coagulation assessment and neuroimaging evaluation should be considered to identify underlying prothrombotic risks and subclinical cerebrovascular disease, even in the absence of overt focal neurological deficits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.